The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

4 months ago

Version History

1 additional source confirmed this story

Version 64 months ago

What changed: Added earnings expectations for Bio-Techne (TECH), highlighting projected EPS decline and operational challenges regarding organic growth and cash flow.

Version 54 months ago

What changed: The story was updated to include Q1 earnings expectations for Thermo Fisher (TMO), specifically highlighting its Life Sciences Solutions and bioproduction segments.

Version 44 months ago

What changed: The story was updated to include MSCI's Q1 earnings outlook, highlighting ETF-linked inflows and AI-driven efficiency as new growth drivers.

Version 34 months ago

What changed: The story was updated to include Danaher's (DHR) Q1 outlook, highlighting bioprocessing demand and the impact of FX headwinds alongside Elevance Health's projections.

Version 24 months ago

What changed: The focus shifted entirely from Pegasystems to Elevance Health's (ELV) upcoming earnings, highlighting expected declines in EPS and operating income.

Version 14 months ago

What changed: The story was updated to focus on Pegasystems' (PEGA) Q1 2026 earnings outlook, highlighting ACV momentum and AI-related competitive risks.

StocksUpdated×6•Originally published 16 April 2026•Updated 17 April 2026•

1 min read

Elevance Health Expected to Report 11.4% EPS Decline Ahead of Q1 Results

Key Facts

1Quest Diagnostics (DGX) is heading into Q1 earnings with steady growth expectations but faces tempering outlooks due to estimate cuts.

2Data indicates a negative Earnings ESP, which could temper the stock's outlook following the results.

Elevance Health (ELV) remains under scrutiny as analysts project an 11.4% decline in earnings per share (EPS) ahead of its quarterly report. Adding to the sector outlook, Bio-Techne (TECH) is expected to report Q3 2026 earnings on May 6, with analysts forecasting a 4% EPS decline to $0.48. The company has faced significant headwinds, including zero organic revenue growth over the last two years and tightening free cash flow margins, though its stock has notably outperformed the healthcare sector ETF (XLV). Meanwhile, investors continue to monitor Thermo Fisher (TMO) and Danaher (DHR) for growth in bioproduction and life sciences. Additionally, MSCI is anticipated to post strong results driven by record ETF-linked inflows and AI-driven efficiencies, reflecting the diverse performance across the healthcare and financial services landscapes.

Sources:

zacks.com